Liver Transplantation Clinical Trial
Official title:
Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy
Open label, randomised, prospective, onecentre Investigator Driven Study:
Comparison of two protocols of immunosuppression after liver Tx in children:
A: Study group - FK506-MMF. Immunosupression protocol: Methylprednisolone 10 mg/kg
intraoperatively i.v. FK506 Day 0 or 1 orally (0,15 mg/kg/D in two doses).MMF max. dosage 30
mg/kg/D p.o. day 0 through day 90.
B. Control group - Tacrolimus, steroids. Immunosupression protocol: Methylprednisolone 10
mg/kg bm intraoperatively Children < 25kg bm: Methylprednisolone taper from 100 mg/D on day
0 to MP 10 mg on day 7 Children > 25kg bm: Methylprednisolone taper from 200 mg/D on day 0
to MP 20 mg on day 7 Week 2-4 Prednisone - 0,5-0,3 mg/kg/D; Week 4-12 Prednisone –0,3-0,2
mg/kg/D; Month 4-6 Prednisone 0,2 – 0,1 mg/kg/D Month 7 – Steroid withdrawal FK506 Day 0 or
1 orally (0,15 mg/kg/D in two doses).
Primary end points:
Number of rejections, number of steroid-resistant rejections.
Secondary end points:
Patients and graft survival Dyslipidemia one year after transplantation Hypertension one
year after transplantation Hyperglycemia/Diabetes de novo one year after transplantation
Renal function before Tx and 1 year after Tx
A: Study group
FK506-MMF.
Immunosupression protocol:
Metylprednisolon 10 mg/kg intraoperatively i.v.
FK506 Day 0 or 1 oraly (0,15 mg/kg/D in two doses).
MMF max. dosage 30 mg/kg/D p.o. day 0 through day 90 according to patient condition and
therapeutic MMF blood concentration
Tailoring:
Immunosupression protocol will be tailored according to the cause of liver failure: patients
with autoimmune liver disease (autoimmune hepatitis, PBC, PSC, overlap syndrome etc) would
be maintained on MMF. All other recipients including cryptogenic liver cirrhosis will be
gradually (over 1 month) withdrawn from MMF administration 90 days after transplantation if
there is:
1. good kidney function (S-creatinin < 150 umol/l) enabling to achieve and maintain
Tacrolimus trough levels above 6 ng/ml and
2. if there was no more than one episode of acute rejection of the graft which resolved
completely.
Targeted Tacrolimus trough levels:
Month 1 - 3 through levels 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 10 – 6 ng/ml
Rejection treatment:
1. Tacrolimus dose adjustment to upper limit of target level if last Tacrolimus trough
level is below the intended limit.
2. Steroid boluses would be administered Metylprednisolon 10 mg/kg daily 3 consecutive
days. No steroid taper. Control biopsy after normalisation of LFTs.
3. After two attacks of acute rejection before MMF disontinuation Prednison dose would be
introduced on at least 0,3 mg/D for 3 months.
4. After second attack of AR after MMF discontinuation Prednison dose would be introduced
on at least 0,3 mg/D for 6 months.
5. Steroid resistant rejection: biopsy proven rejection persisting after three courses of
steroid pulses. Steroid resistant rejection would be treated according to local praxis.
Concomitant drugs:
Antiviral and antibacterial prophylaxis according to current centre praxis. Prophylaxis of
cholestasis and prophylaxis/treatment of the bone disease where applicable.
B. Control group
Tacrolimus, steroids.
Immunosupression protocol:
Metylprednisolon 10 mg/kg bm intraoperatively Children < 25kg bm: Metylprednisolon taper
from 100 mg/D on day 0 to MP 10 mg on day 7 Children > 25kg bm: Metylprednisolon taper from
200 mg/D on day 0 to MP 20 mg on day 7 Week 2-4 Prednison - 0,5-0,3 mg/kg/D Week 4-12
Prednison –0,3-0,2 mg/kg/D Month 4-6 Prednison 0,2 – 0,1 mg/kg/D Month 7 – Steroid
withdrawal
FK506 Day 0 or 1 orally (0,15 mg/kg/D in two doses).
Intended Tacrolimus trough levels:
Month 1 –3 through levels 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 6-10 ng/ml
Rejection treatment:
1. Tacrolimus dose adjustment to upper limit of target level if last Tacrolimus trough
level is below the intended limit.
2. Steroid boluses would be administered Metylprednisolon 10 mg/kg bm daily 3 consecutive
days. No steroid taper, return to previous steroid dose. Control biopsy after
normalisation of LFTs.
3. After two attacks of acute rejection Prednison dose would be maintained on at least 0,3
mg/D for 3 months.
4. Steroid resistant rejection: biopsy proven rejection persisting after three courses of
steroid pulses. Steroid resistant rejection would be treated according to local praxis.
Biopsy: Liver biopsy should be taken in any suspicion of graft rejection or disease
recurrence. Protocol biopsy would be taken according to local practice, liver biopsy in
one-year after transplantation is mandatory.
Primary end points:
Number of rejections, number of steroid-resistant rejections.
Secondary end points:
Patients and graft survival Dyslipidemia one year after transplantation Hypertension one
year after transplantation Hyperglycemia/Diabetes de novo one year after transplantation
Renal function before Tx and 1 year after Tx
Inclusion criteria:
Subjects who meet all of the following criteria are eligible for this study:
1. Male or female patients, not older than 18 years old.
2. Primary liver transplantation
3. Patient is capable of understanding the purpose and risks of the study and has been
informed both orally and in writing and has given informed consent
Exclusion criteria:
Subjects who meet one or more of the following criteria are not eligible for this study:
1. Female patients who are pregnant or are breast feeding
2. Patients > 18 years old
3. Combined liver-kidney transplantation
4. Recipient of second liver graft
5. Patients are allergic, hyper-sensitive or intolerant to HCO-60 or structurally related
compounds, macrolide antibiotics or tacrolimus.
6. Patients with known HIV-anamnesis
7. Patient requires ongoing dosing with a systemic immunosuppressive drug at study entry
for another indication than the prophylaxis of liver graft rejection
8. Patient has significant, uncontrolled concomitant infections and/or severe diarrhea,
vomiting, or active peptic ulcer.
9. Patient is participating or has participated in another clinical study and/or is taking
or has been taking an investigational drug in the past 28 days.
10. Other reasons which depend on the assessment of the physician (no MMF will be given to
patients with severe persistent hypersplenism (WBC < 3.500/ml, platelets < 50.000/ml)
Informed Consent:
Patient, who will give written consent for participation in the study and will fulfil all
the inclusion and exclusion criteria, will be included in the study. After inclusion into
the study, the patient may withdraw at any time for any reason.
Follow-up: (time of one patient observation ) -12 months
Number of centers: 1 Number of patients: 40 Indication: - Primary Liver transplantation
Duration of study: 36 months Enrollment period: 18 months
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |